Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H1 2018, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.
Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibers could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 25, 28, 110, 24 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 33 and 2 molecules, respectively.
Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc
Abide Therapeutics Inc
Acadia Pharmaceuticals Inc
Achelios Therapeutics Inc
Adynxx Inc
Affectis Pharmaceuticals AG
Amneal Pharmaceuticals Inc
AnaBios Corp
Anavex Life Sciences Corp
AngioChem Inc
Aptinyx Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Asahi Kasei Pharma Corp
Astellas Pharma Inc
AstraZeneca Plc
Aucta Pharmaceuticals LLC
BCI Pharma SA
BCN Peptides SA
Biogen Inc
Bionomics Ltd
Can-Fite BioPharma Ltd
Cara Therapeutics Inc
Cavion LLC
Celgene Corp
Cellix Bio Pvt Ltd
Centrexion Therapeutics Corp
Cerecor Inc
CerSci Therapeutics Inc
Chromocell Corp
Circuit Therapeutics Inc
Colby Pharmaceutical Co
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Develco Pharma Schweiz AG
Dompe Farmaceutici SpA
Eisai Co Ltd
Eli Lilly and Co
Endece LLC
Evec Inc
Genecode AS
GL Pharm Tech Corp
Glialogix Inc
Grunenthal GmbH
GT Biopharma Inc
GW Pharmaceuticals Plc
Hydra Biosciences Inc
Immune Pharmaceuticals Inc
India Globalization Capital Inc
Intec Pharma Ltd
Integral Molecular Inc
Intellipharmaceutics International Inc
Ionis Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
JT Pharmaceuticals Inc
Kancera AB
Knopp Biosciences LLC
Kolon Life Science Inc
Komipharm International Co Ltd
Lexicon Pharmaceuticals Inc
Lohocla Research Corp
Mapi Pharma Ltd
MD Biosciences GmbH
Medifron DBT Co Ltd
MEDRx Co Ltd
Merck & Co Inc
MindImmune Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Mundipharma International Ltd
Nanomerics Ltd
Neurim Pharmaceuticals Ltd
Neurocentrx Pharma Ltd
NeuroCycle Therapeutics GmbH
Neurodyn Life Sciences Inc
NeuroMax Ltd
NeurOp Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
Nippon Zoki Pharmaceutical Co Ltd
NoNO Inc
Novartis AG
Novassay SA
OliX Pharmaceuticals Inc
Orexigen Therapeutics Inc
Patagonia Pharmaceuticals LLC
Pfizer Inc
Pharmaleads SA
Phosphagenics Ltd
Quartet Medicine Inc
RaQualia Pharma Inc
Re-Pharm Ltd
Relmada Therapeutics Inc
Revance Therapeutics Inc
Rottapharm Biotech Srl
Saniona AB
Shionogi & Co Ltd
Sollis Therapeutics Inc
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
Theranexus SAS
Toray Industries Inc
Trevena Inc
Vertex Pharmaceuticals Inc
Virobay Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Yooyoung Pharm Co Ltd
Yuhan Corp
'
Table of Contents
Table of Contents 2
Introduction 9
Neuropathic Pain - Overview 10
Neuropathic Pain - Therapeutics Development 11
Neuropathic Pain - Therapeutics Assessment 37
Neuropathic Pain - Companies Involved in Therapeutics Development 54
Neuropathic Pain - Drug Profiles 103
Neuropathic Pain - Dormant Projects 412
Neuropathic Pain - Discontinued Products 431
Neuropathic Pain - Product Development Milestones 436
Appendix 446
List of Tables
Number of Products under Development for Neuropathic Pain, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Products under Development by Universities/Institutes, H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Neuropathic Pain - Pipeline by AbbVie Inc, H1 2018
Neuropathic Pain - Pipeline by Abide Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Adynxx Inc, H1 2018
Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H1 2018
Neuropathic Pain - Pipeline by Amneal Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by AnaBios Corp, H1 2018
Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H1 2018
Neuropathic Pain - Pipeline by AngioChem Inc, H1 2018
Neuropathic Pain - Pipeline by Aptinyx Inc, H1 2018
Neuropathic Pain - Pipeline by Araim Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Artelo Biosciences Inc, H1 2018
Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp, H1 2018
Neuropathic Pain - Pipeline by Astellas Pharma Inc, H1 2018
Neuropathic Pain - Pipeline by AstraZeneca Plc, H1 2018
Neuropathic Pain - Pipeline by Aucta Pharmaceuticals LLC, H1 2018
Neuropathic Pain - Pipeline by BCI Pharma SA, H1 2018
Neuropathic Pain - Pipeline by BCN Peptides SA, H1 2018
Neuropathic Pain - Pipeline by Biogen Inc, H1 2018
Neuropathic Pain - Pipeline by Bionomics Ltd, H1 2018
Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Cavion LLC, H1 2018
Neuropathic Pain - Pipeline by Celgene Corp, H1 2018
Neuropathic Pain - Pipeline by Cellix Bio Pvt Ltd, H1 2018
Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H1 2018
Neuropathic Pain - Pipeline by Cerecor Inc, H1 2018
Neuropathic Pain - Pipeline by CerSci Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Chromocell Corp, H1 2018
Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Colby Pharmaceutical Co, H1 2018
Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H1 2018
Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H1 2018
Neuropathic Pain - Pipeline by Eisai Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Eli Lilly and Co, H1 2018
Neuropathic Pain - Pipeline by Endece LLC, H1 2018
Neuropathic Pain - Pipeline by Evec Inc, H1 2018
Neuropathic Pain - Pipeline by Genecode AS, H1 2018
Neuropathic Pain - Pipeline by GL Pharm Tech Corp, H1 2018
Neuropathic Pain - Pipeline by Glialogix Inc, H1 2018
Neuropathic Pain - Pipeline by Grunenthal GmbH, H1 2018
Neuropathic Pain - Pipeline by GT Biopharma Inc, H1 2018
Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H1 2018
Neuropathic Pain - Pipeline by Hydra Biosciences Inc, H1 2018
Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by India Globalization Capital Inc, H1 2018
Neuropathic Pain - Pipeline by Intec Pharma Ltd, H1 2018
Neuropathic Pain - Pipeline by Integral Molecular Inc, H1 2018
Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc, H1 2018
Neuropathic Pain - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H1 2018
Neuropathic Pain - Pipeline by JT Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Kancera AB, H1 2018
Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H1 2018
Neuropathic Pain - Pipeline by Kolon Life Science Inc, H1 2018
Neuropathic Pain - Pipeline by Komipharm International Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Lexicon Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Lohocla Research Corp, H1 2018
Neuropathic Pain - Pipeline by Mapi Pharma Ltd, H1 2018
Neuropathic Pain - Pipeline by MD Biosciences GmbH, H1 2018
Neuropathic Pain - Pipeline by Medifron DBT Co Ltd, H1 2018
Neuropathic Pain - Pipeline by MEDRx Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Merck & Co Inc, H1 2018
Neuropathic Pain - Pipeline by MindImmune Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Neuropathic Pain - Pipeline by Mundipharma International Ltd, H1 2018
Neuropathic Pain - Pipeline by Nanomerics Ltd, H1 2018
Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2018
Neuropathic Pain - Pipeline by Neurocentrx Pharma Ltd, H1 2018
Neuropathic Pain - Pipeline by NeuroCycle Therapeutics GmbH, H1 2018
Neuropathic Pain - Pipeline by Neurodyn Life Sciences Inc, H1 2018
Neuropathic Pain - Pipeline by NeuroMax Ltd, H1 2018
Neuropathic Pain - Pipeline by NeurOp Inc, H1 2018
Neuropathic Pain - Pipeline by Newron Pharmaceuticals SpA, H1 2018
Neuropathic Pain - Pipeline by Nippon Chemiphar Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H1 2018
Neuropathic Pain - Pipeline by NoNO Inc, H1 2018
Neuropathic Pain - Pipeline by Novartis AG, H1 2018
Neuropathic Pain - Pipeline by Novassay SA, H1 2018
Neuropathic Pain - Pipeline by OliX Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Orexigen Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Patagonia Pharmaceuticals LLC, H1 2018
Neuropathic Pain - Pipeline by Pfizer Inc, H1 2018
Neuropathic Pain - Pipeline by Pharmaleads SA, H1 2018
Neuropathic Pain - Pipeline by Phosphagenics Ltd, H1 2018
Neuropathic Pain - Pipeline by Quartet Medicine Inc, H1 2018
Neuropathic Pain - Pipeline by RaQualia Pharma Inc, H1 2018
Neuropathic Pain - Pipeline by Re-Pharm Ltd, H1 2018
Neuropathic Pain - Pipeline by Relmada Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Revance Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Rottapharm Biotech Srl, H1 2018
Neuropathic Pain - Pipeline by Saniona AB, H1 2018
Neuropathic Pain - Pipeline by Shionogi & Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Sollis Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Sorrento Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Neuropathic Pain - Pipeline by Theranexus SAS, H1 2018
Neuropathic Pain - Pipeline by Toray Industries Inc, H1 2018
Neuropathic Pain - Pipeline by Trevena Inc, H1 2018
Neuropathic Pain - Pipeline by Vertex Pharmaceuticals Inc, H1 2018
Neuropathic Pain - Pipeline by Virobay Inc, H1 2018
Neuropathic Pain - Pipeline by VistaGen Therapeutics Inc, H1 2018
Neuropathic Pain - Pipeline by Vitality Biopharma Inc, H1 2018
Neuropathic Pain - Pipeline by Yooyoung Pharm Co Ltd, H1 2018
Neuropathic Pain - Pipeline by Yuhan Corp, H1 2018
Neuropathic Pain - Dormant Projects, H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..1), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..2), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..3), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..4), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..5), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..6), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..7), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..8), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..9), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..10), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..11), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..12), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..13), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..14), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..15), H1 2018
Neuropathic Pain - Dormant Projects, H1 2018 (Contd..16), H1 2018
Neuropathic Pain - Discontinued Products, H1 2018
Neuropathic Pain - Discontinued Products, H1 2018 (Contd..1), H1 2018
Neuropathic Pain - Discontinued Products, H1 2018 (Contd..2), H1 2018
Neuropathic Pain - Discontinued Products, H1 2018 (Contd..3), H1 2018
Neuropathic Pain - Discontinued Products, H1 2018 (Contd..4), H1 2018
List of Figures
Number of Products under Development for Neuropathic Pain, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
